This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Medical Stocks to Buy in 2022 for Long-Term Resilience
by Indrajit Bandyopadhyay
Here we discuss two Medical companies, VRTX, ISRG and AMN, that may prove to be wealth creators for investors over the long term on the back of their strong fundamentals.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $111.75 in the latest trading session, marking a -1.51% move from the prior day.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Thermo Fisher (TMO) Launches New TaqPath Panel in Europe
by Zacks Equity Research
This panel of Thermo Fisher (TMO), apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast.
Charles River's (CRL) New Launch to Boost Gene Therapy Workflow
by Zacks Equity Research
Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.
If You Invested $1000 in AMN Healthcare Services a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.
Wall Street Analysts See a 28% Upside in AMN Healthcare (AMN): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.4% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $111.66, moving +0.1% from the previous trading session.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.
SmileDirectClub (SDC) Hurt by Lower Spending, Margin Woe
by Zacks Equity Research
The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.
Should Value Investors Buy AMN Healthcare Services (AMN) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist
by Zacks Equity Research
Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Veeva Systems' (VEEV) Latest Launches to Enhance Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) new offerings are expected to aid the marketing and field teams with more accurate and actionable insights into patient and HCP touchpoints.
Zacks.com featured highlights include Scorpio Tankers, AMN Healthcare Services, KnowBe4 and BJ's Wholesale Club Holdings
by Zacks Equity Research
Scorpio Tankers, AMN Healthcare Services, KnowBe4 and BJ's Wholesale Club Holdings are part of Zacks Screen of the Week article.
AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $106.50, marking a +0.57% move from the previous day.
Factors That Make Centene (CNC) an Attractive Bet for Investors
by Zacks Equity Research
Centene (CNC) rides on continued top-line growth and numerous contract wins. Divestitures and an adequate cash-generating ability equip CNC well to invest in growth-related initiatives.
Merit Medical (MMSI) Launches New Soft Tissue Biopsy System
by Zacks Equity Research
Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Sail Through Market Volatility With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Scorpio Tankers (STNG), AMN Healthcare (AMN), KnowBe4 (KNBE) and BJ's Wholesale (BJ) are poised to gain.
PacBio's (PACB) New Method for TR Profiling Now Available
by Zacks Equity Research
PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.
3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.